4-氯甲基-2-(4-氯苯基)-1,3-噁唑 | 22091-36-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-氯甲基-2-(4-氯苯基)-1,3-噁唑
• 英文名称: 4-chloromethyl-2-(4-chlorophenyl)oxazole
• 英文别名: 2-(4-chlorophenyl)-4-chloromethyl-oxazole；4-(Chloromethyl)-2-(4-chlorophenyl)-1,3-oxazole
• CAS: 22091-36-7
• 化学式: C₁₀H₇Cl₂NO
• mdl: MFCD07687118
• 分子量: 228.078
• InChiKey: BGGPUCCJQGIJRL-UHFFFAOYSA-N

物化性质

• 熔点：
  90-91 °C
• 沸点：
  348.6±52.0 °C(Predicted)
• 密度：
  1.338±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  4-氯甲基-2-(4-氯苯基)-1,3-噁唑 在 potassium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 2-(2-(4-chlorophenyl)oxazol-4-yl)acetonitrile
  参考文献：
  名称：

  COMPOUNDS AND METHODS for the inhibition of HDAC

  摘要：

  公开号：

  EP2533783B1
• 作为产物：
  描述：

  methyl 2-(4-chlorophenyl)-1,3-oxazole-4-carboxylate 在 lithium aluminium tetrahydride 、 氯化亚砜 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 4-氯甲基-2-(4-氯苯基)-1,3-噁唑
  参考文献：
  名称：

  Discovery of the disubstituted oxazole analogues as a novel class anti-tuberculotic agents against MDR- and XDR-MTB

  摘要：

  A high-throughput screening effort on 45,000 compounds resulted in the discovery of a disubstituted oxazole as a new structural class inhibitor of Mycobacterium tuberculosis (Mtb). In order to improve the activity and investigate the SAR of this scaffold, a series of disubstituted azole analogues have been designed and synthesized. The newly synthesized compounds 1a-y were evaluated for their in vitro anti-TB activity versus replicating, multi-and extensive drug resistant Mtb strains. All the compounds, except 1o, 1p and 1q, showed potent anti-TB activity with MIC of 1-64 mg/L. The test of broad spectrum panel revealed that this series are specific to Mtb. The cytotoxicity assessment indicated that the compounds were not cytotoxic against HEK 293 cells. The compounds could have a novel mechanism to anti-Mtb as they can inhibit drug sensitive and drug resistant Mtb. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.09.072

文献信息

• ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION
  申请人：Zablocki Jeff

  公开号：US20080032995A1

  公开（公告）日：2008-02-07

  Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.

  揭示了具有以下结构的新型异黄酮衍生物，其可用作ALDH-2抑制剂，用于治疗哺乳动物对成瘾药物的依赖，例如对多巴胺类药物如可卡因、吗啡、安非他命、尼古丁和酒精的依赖。
• ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS
  申请人：Diamond Ivan

  公开号：US20090124672A1

  公开（公告）日：2009-05-14

  Disclosed are isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for use treating in mammals suffering from psychiatric disorders such as, for example, depression, generalized anxiety, social phobia, panic disorder, and sleep disorders.

  披露的是具有公式I结构的异黄酮衍生物，它们作为ALDH-2抑制剂，用于治疗遭受精神疾病困扰的哺乳动物，例如抑郁症、广泛性焦虑症、社交恐惧症、恐慌症和睡眠障碍。
• [EN] ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION<br/>[FR] INHIBITEURS D'ALDH-2 DANS LE TRAITEMENT D'UNE ACCOUTUMANCE
  申请人：CV THERAPEUTICS INC

  公开号：WO2009094028A1

  公开（公告）日：2009-07-30

  Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.

  揭示了具有Formula I结构的新型异黄酮衍生物，可用作ALDH-2抑制剂，用于治疗哺乳动物对成瘾药物的依赖，例如对多巴胺类药物如可卡因、吗啡、安非他命、尼古丁和酒精的依赖。
• Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus
  申请人：Wyeth

  公开号：US20030216442A1

  公开（公告）日：2003-11-20

  This invention provides compounds of formula I, having the structure 1 wherein R 1 , R 4 , A, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof, that are useful in treating metabolic disorders mediated by insulin resistance or hyperglycemia.

  这项发明提供了具有结构的I式化合物，其结构如下： 其中R 1 ，R 4 ，A和Z如规范中定义，或其药学上可接受的盐，可用于治疗由胰岛素抵抗或高血糖介导的代谢紊乱。
• AMINO ACID ESTER PRODRUGS AND THE USE THEREOF
  申请人：Meibom Daniel

  公开号：US20110237629A1

  公开（公告）日：2011-09-29

  The present application relates to amino acid ester prodrug derivatives of 2-amino-6-([2-(4-chlorophenyl)-1,3-oxazol-4-yl]methyl}sulfanyl)-4-(4-[2,3-dihydroxypropyl]oxy}phenyl)pyridine-3,5-dicarbonitriles, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of cardiovascular disorders.

  本申请涉及2-氨基-6-([2-(4-氯苯基)-1,3-噁唑-4-基]甲基}硫基)-4-(4-[2,3-二羟基丙基]氧基}苯基)吡啶-3,5-二羧腈的氨基酸酯前药衍生物，其制备方法，它们用于治疗和/或预防疾病的用途，以及它们用于制造用于治疗和/或预防疾病的药物，特别是心血管疾病。